Цитата:
Сообщение от BMB
"...самый дешевый и принимал его до тех пор, пока достигалась поставленная цель" не думаю, что дешевизна непременно должна означать более слабый препарат. Достижение цели по уровню ЛПНП более слабым статином может оказаться в итоге дороже, чем достижение той же цели у того же пациента статином посильнее.
|
Коллега, по моему зря Вы отмахнулись от мнения известного Dr. S. Grundi.
А как Вы это прокомментируете? Неужели и здесь не ведают?
Lipid modification
Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
[Ссылки доступны только зарегистрированным пользователям ]
Statins for primary prevention
When the decision has been made to prescribe a statin, it is recommended that therapy should usually be initiated with a drug with a low acquisition cost (taking into account required daily dose and product price per dose).
Treatment for the primary prevention of CVD should be initiated with simvastatin 40 mg. If there are potential drug interactions, or simvastatin 40 mg is contraindicated, a lower dose or alternative preparation such as pravastatin may be chosen.
1.4.8 Higher intensity statins
A target for total or LDL cholesterol is not recommended for people who are treated with a statin for primary prevention of CVD. should not routinely be offered to people for the primary prevention of CVD.
Statins for secondary prevention
When the decision has been made to prescribe a statin, it is recommended that therapy should usually be initiated with a drug with a low acquisition cost (taking into account required daily dose and product price per dose).20
Treatment for the secondary prevention of CVD should be initiated with simvastatin 40 mg. If there are potential drug interactions, or simvastatin 40 mg is contraindicated, a lower dose or alternative preparation such as pravastatin may be chosen.
People with acute coronary syndrome should be treated with a higher intensity statin Any decision to offer a higher intensity statin should take into account the patient's informed preference Any decision to offer a higher intensity statin should take into account the patient's informed preference,comorbidities, multiple drug therapy, and the benefits and risks of treatment.